Effects of pravastatin on chronic rejection of rat cardiac allografts

Transplantation

Volumn 65, Issue 2, 1998, Pages 149-155

  Maggard, Melinda A ^a   Bibo, K E ^a   Wang, Tao ^a   Kaldas, Fady ^a   Seu, Philip ^a   Busuttil, Ronald W ^a   Imagawa, David K ^a,b,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Transportation Research Institute   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; FIBRONECTIN; LAMININ; PRAVASTATIN; SCLEROPROTEIN;

ALLOGRAFT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GRAFT REJECTION; HEART TRANSPLANTATION; IMMUNOHISTOCHEMISTRY; INTRAMUSCULAR DRUG ADMINISTRATION; MACROPHAGE; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; T LYMPHOCYTE;

EID: 0344863177     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199801270-00001     Document Type: Article

References (30)

1. Tilney NL, Whitley WD, Diamond JR, Kupiec-Weglinski JW, Adams D. Chronic rejection: an undefined conundrum. Transplantation 1991; 52: 389.
2. Gao SZ, Schroeder JS, Aldeman EL, et al. Prevalence of accelerated coronary artery disease in heart transplant survivors. Circulation 1989; Suppl 3: 422.
3. Heck CF, Shumway SJ, Kaye MP. The registry of the International Society for Heart Transplantation: sixth official report -1989. J Heart Transplant 1989; 8: 271.
4. Oguma S, Banner B, Zerbe T, et al. Participation of dendritic cells in vascular lesions of chronic rejection of human allografts. Lancet 1988; 2: 933.
5. Hruban RH, Beschorner WE, Baumgartner WA. Accelerated arteriosclerosis in heart transplant recipients is associated with a T-lymphocyte-mediated endothelialitis. Am J Pathol 1990; 137: 871.
6. Usy CJ, Rose AG. Cardiac transplantation: aspects of the pathology. Pathol Annu 1983; 17: 147.
7. Timpl R, Dziadek M. Structure, development, and molecular pathology of basement membranes. Int Rev Exp Pathol 1986; 29: 1.
8. Martin GR, Timpl R. Laminin and other basement membranes components. Annu Rev Cell Biol 1987; 3: 57.
9. Coito AJ, Binder J, De Sousa M, Kupiec-Weglinski JW. The expression of extracellular matrix proteins during accelerated rejection of cardiac allografts in sensitized rats. Transplantation 1994; 57: 599.
10. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425.
11. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood pressure in adults (Adult Treatment Panel II). JAMA 1993; 269: 3015.
12. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621.
13. Adams DH, Tilney NL, Collins JJ Jr, Karnovsky MJ. Experimental graft arteriosclerosis: I. The Lewis-to-F-344 allograft model. Transplantation 1992; 53: 1115.
14. Ono K, Lindsey ES. Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg 1969; 547: 255.
15. Orosz CG. Endothelial activation and chronic allograft rejection. Clin Transplant 1994; 8: 299.
16. Jutila MA. Role of changes in the vascular endothelium in chronic inflammation. Clin Transplant 1994; 8: 304.
17. Karnovsky MJ, Russell ME, Hancock W, et al. Chronic rejection in experimental cardiac transplantation in a rat model. Clin Transplant 1994; 8: 308.
18. Clausell N, Mosossi S, Rabinovitch M. Increased interleukin-1β and fibronectin expression are early features of the development of the postcardiac transplant coronary arteriopathy in piglets. Am J Pathol 1993; 142: 1772.
19. Coito AJ, Binder J, Brown LF, de Sousa M, Van De Water L, Kupiec-Weglinski JW. Anti-TNF-α treatment down-regulates the expression of fibronectin and decreases cellular infiltration of cardiac allografts in rats. J Immunol 1995; 154: 2949.
20. Hines KL, Kulkarni AB, McCarthy JB, et al. Synthetic fibronectin peptides interrupt inflammatory cell infiltration in transforming growth factor-β1 knockout mice. Proc Natl Acad Sci USA 1994; 91: 5187.
21. Molossi S, Elices M, Arrhenius T, Diaz R, Coluber C, Rabinovitch M. Blockade of very late antigen-4 integrin to fibronectin with connecting segment-1 peptides reduces accelerated coronary arteriopathy in rabbit cardiac allografts. J Clin Invest 1995; 95: 2601.
22. Adams DH, Karnovsky MJ. Hypercholesterolemia does not exacerbate arterial intimai thickening in chronically rejecting rat cardiac allografts. Transplant Proc 1989; 21: 437.
23. Handa N, Hatanaka M, Baumgartner WA, et al. Late cyclosporine treatment ameliorates established coronary graft disease in rat allografts. Transplantation 1993; 56: 535.
24. Katznelson A, Wilkinson AH, Kobashigawa JA, et al. The effect of pravastatin on acute rejection after kidney transplantation: a pilot study. Transplantation 1996; 61: 1469.
25. Imagawa DK, Dawson S III, Holt CD, et al. Hyperlipidemia after liver transplantation. Transplantation 1996; 62: 934.
26. Kakkis JL, Ke B, Dawson S, et al. Pravastatin increases survival and inhibits natural killer cell enhancement factor (NKEF) in liver transplanted rats. J Surg Res 1997; 69: 393.
27. Cutts JL, Bankhurst AD. Reversal of lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin-2. J Cell Physiol 1990; 145: 244.
28. McPherson R, Tsoukas C, Baines MG, et al. Effects of lovastatin on natural killer cell function and other immunological parameters in man. J Clin Immunol 1993; 13: 439.
29. Kobashigawa JA, Moriguchi JA, Sabad A, et al. Cyclosporine and pravastatin pharmacokinetics in cardiac transplant recipients. J Heart Lung Transplant 1997; 16: 84.
30. Sinensky M, Beck LA, Leonard S, Evans R. Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis. J Biol Chem 1990; 265: 19937.